Tarsus Pharmaceuticals INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersIrvine, CA
US patents9
SAM.gov UEIYJBRXANG28R5
CAGE code9MLX1
Incorporated inDE
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
9 US patents granted 2020–2025, 9 of them in the five years to SEP 2025.
Pharmaceuticals 9
- Isoxazoline parasiticide formulationsUS 12,364,685 · granted JUL 22, 2025
- Pharmaceutical compositions for demodex related blepharitis and eyelid crustingUS 12,257,263 · granted MAR 25, 2025
- Isoxazoline parasiticide formulationsUS 12,213,964 · granted FEB 4, 2025
- Isoxazoline parasiticide formulations and methods for treating blepharitisUS 12,171,750 · granted DEC 24, 2024
- Ophthalmic compositions for treating ocular Demodex using lotilaner formulationsUS 11,752,137 · granted SEP 12, 2023
Newest 5 shown · Granted to Tarsus Pharmaceuticals, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Tarsus Pharmaceuticals INC | Irvine | CA | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.